Abbott Laboratories

ABT

$109.45

-2.7% last 12 months

Polen Capital Holding value: $2.45 Billion Ken Fisher Holding value: $998 Million Jim Simons Holding value: $344 Million Ray Dalio Holding value: $333 Million Jeremy Grantham Holding value: $180 Million Ken Griffin Holding value: $90.4 Million Joel Greenblatt Holding value: $12.1 Million Mario Gabelli Holding value: $2.6 Million Tom Russo Holding value: $1.34 Million Steven Cohen Holding value: $0 Chuck Akre Holding value: $0 Tom Gayner Holding value: $0 Daniel Loeb Holding value: $0 Chris Davis Holding value: $0 Stanley Druckenmiller Holding value: $0 George Soros Holding value: $0 Bill Gates Holding value: $0 Donald Yacktman Holding value: $0 David Tepper Holding value: $0 Prem Watsa Holding value: $0

Market Cap

$186 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$101.24 - $141.53

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

24.07x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$1.83 (1.72%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $186 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $195 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $1.83 (1.72%)
1 Year Return Profit or loss of share price change plus dividend yield. -1.0%
52-Week High Highest share price in the last 52 weeks. $141.53
52-Week Low Lowest share price in the last 52 weeks. $101.24
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.76
Outstanding Shares The number of shares the company has issued and are held by stockholders. 1.75 Billion
Avg 30 Day Volume The number of shares traded in the last 30 days. 5.14 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 24.07
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 66.0
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $4.33
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 4.38
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 5.47
Enterprise Value to Revenue Enterprise value divided by revenue 4.38
Enterprise Value to EBIT Enterprise Value divided by EBIT 21.12
Total Debt to Enterprise Value Total debt divided by enterprise value 0.09
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.48

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $44.5 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $25.4 Billion
EBIT Earnings before tax and interest payments. $9.23 Billion
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $7.73 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 17.35%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +36.5%
Return on Equity Equity divided by market cap. 21.82%
Return on Assets Indicates a company's profitability in relation to its total assets. 10.44%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 15.04%

Insider trades

No purchases

135,925.0 shares sold (1 transactions)

No purchases

90,200.0 shares sold (5 transactions)

No purchases

4,462.0 shares sold (2 transactions)

No purchases

No sells

Q3 2021 Q4 2021 Q1 2022 Q2 2022

About Abbott Laboratories

CEO: Robert Ford

Industry: Pharmaceutical Preparation Manufacturing

Similar stocks

Johnson & Johnson
Johnson & Johnson
Pfizer Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
Hologic, Inc.
Hologic, Inc.
Medtronic Plc
Medtronic Plc
Boston Scientific Corp.
Boston Scientific Corp.
Astrazeneca plc - ADR
Astrazeneca plc - ADR
Novartis AG - ADR
Novartis AG - ADR
Glaxosmithkline plc - ADR
Glaxosmithkline plc - ADR

News

Here''s How Much $1000 Invested In Abbott Laboratories 5 Years Ago Would Be Worth Today

Here''s How Much $1000 Invested In Abbott Laboratories 5 Years Ago Would Be Worth Today

Abbott Laboratories (NYSE: ABT ) has outperformed the market over the past 5 years by 7.3% on an annualized basis producing an average annual return of 17.14...

Benzinga Benzinga, 2 days ago
''Absurd'' loophole can''t keep Abbott formula lawsuits in federal court -judge

''Absurd'' loophole can''t keep Abbott formula lawsuits in federal court -judge

Abbott Laboratories Inc cannot use a controversial legal loophole known as "snap removal" to keep lawsuits claiming that its Similac baby formula caused a de...

Reuters Reuters, 3 days ago
Baby formula warning after FDA investigates TENTH infant death linked to Abbott Laboratories

Baby formula warning after FDA investigates TENTH infant death linked to Abbott Laboratories

THE FDA has announced that it was notified of another baby formula-related infant death, new documents show. This comes after as many as nine children have d...

The Sun The Sun, 4 days ago
Finally, a Reasonable Price For This Healthcare Blue Chip

Finally, a Reasonable Price For This Healthcare Blue Chip

Abbott Laboratories is a blue chip worth scooping up when it goes on sale.

The Motley Fool The Motley Fool, 6 days ago
Never miss a trade
To improve your user experience we use cookies.